LASA Supergenerics discloses related party transactions for Q4FY26

1 min read     Updated on 30 May 2026, 10:13 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

LASA Supergenerics Limited disclosed related party transactions for Q4FY26, reporting ₹35.36 lakh in actual transactions against an approved limit of ₹618 lakh. Payments included remuneration for directors and a donation to the Dr Omkar Herlekar Foundation.

powered bylight_fuzz_icon
41704972

*this image is generated using AI for illustrative purposes only.

Lasa Supergenerics Limited has disclosed its related party transactions for the quarter and year ended March 31, 2026. The filing, submitted to the stock exchanges on May 29, 2026, details payments made to directors, key managerial personnel, and a foundation connected to the company. The total value of transactions executed during the reporting period amounted to ₹35.36 lakh, against an approved limit of ₹618 lakh by the audit committee.

The disclosures were made in compliance with Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The transactions primarily cover remuneration, sitting fees, and donations. The company’s Chairman and Managing Director, Omkar Herlekar, received ₹3 lakh, while Whole Time Directors Umesh Pawar, Prathmesh Chalke, and Ganesh Potdar received ₹1.49 lakh, ₹4.63 lakh, and ₹0.30 lakh respectively.

Breakdown of Transactions

The following table summarizes the key related party transactions reported for the period:

Related Party Relationship Transaction Type Approved Value (₹ lakh) Reporting Period Value (₹ lakh)
Mr. Omkar Herlekar Promoter-Managing Director Directors Remuneration 100 3.00
Mr. Umesh Pawar Whole Time Director Directors Remuneration 100 1.49
Mrs Mitti Jain Company Secretary Remuneration 100 5.59
Dr Omkar Herlekar Foundation Common Director Donation Given 200 15.50
Mr. Prathmesh Chalke Whole Time Director Directors Remuneration 8 4.63

Independent Directors received sitting fees for their participation in board meetings. Ms. Ekta Gurnasinghani, Mr. Hardesh Tolani, and Ms. Manali Bhagtani each received ₹0.75 lakh. Other independent directors, including Ms. Ajay Sukhwani, Mr. Yogesh Hari Ughada, Mr. Pravin Gadalya Lachake, Mr. Ketan Bhau Songal, and Ms. Rekha Hemant Wakh, received amounts ranging from ₹0.10 lakh to ₹1.00 lakh.

The Chief Financial Officers (CFOs), Mr. Ravi Shankar Kabra and Ms. Varsha Joshi, were remunerated ₹0 and ₹1.20 lakh respectively during the quarter. The audit committee had previously approved a total remuneration limit of ₹30 lakh for Mr. Kabra and ₹8 lakh for Ms. Joshi.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.84%+1.71%+2.72%-12.80%-47.96%-89.34%

How will the company's related party transaction strategy evolve as it approaches the next fiscal year?

What impact might the significant donation to the Dr Omkar Herlekar Foundation have on future corporate social responsibility initiatives?

Could the disparity in remuneration limits versus actual payouts signal a shift in executive compensation policies?

Lasa Supergenerics narrows net loss to ₹416.44 lakh in Q4FY26

1 min read     Updated on 30 May 2026, 10:02 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Lasa Supergenerics narrowed its net loss to ₹416.44 lakh for Q4FY26 from ₹1,429.11 lakh in Q4FY25, with revenue from operations falling to (₹13.15) lakh due to a production halt caused by a fire incident. The statutory auditor, Gupta Rustagi & Co., issued a qualified opinion due to insufficient evidence on the fire's financial impact and the lack of impairment assessment for intangible assets worth ₹1,667.05 lakh. For the full year FY26, the company reported a net loss of ₹3,409.03 lakh on a total income of ₹2,534.05 lakh, while facing operational challenges like labour unrest.

powered bylight_fuzz_icon
41621233

*this image is generated using AI for illustrative purposes only.

Lasa Supergenerics reported a net loss of ₹416.44 lakh for the quarter ended March 31, 2026, a significant improvement from the net loss of ₹1,429.11 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at (₹13.15) lakh, a steep decline from ₹3,913.77 lakh in Q4FY25, primarily due to a complete halt in production following a fire incident at its Ratnagiri factory. The company’s total income for the quarter was (₹9.08) lakh.

The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The statutory auditor, Gupta Rustagi & Co., issued a qualified opinion on the financial results. The qualification cites insufficient appropriate audit evidence regarding the completeness and accuracy of the financial impact of the fire incident that occurred on May 18, 2025. Additionally, the auditor qualified the opinion regarding the impairment of intangible assets, which include patents, goodwill, and software aggregating to ₹1,667.05 lakh, as the company has not carried out an impairment assessment.

Financial Performance

Particulars Quarter ended Mar 31, 2026 (₹ in Lakhs) Quarter ended Mar 31, 2025 (₹ in Lakhs)
Revenue from Operations (13.15) 3,913.77
Total Income (9.08) 4,152.94
Total Expenses 342.32 3,973.16
Net Profit / (Loss) (416.44) (1,429.11)
Earnings Per Share (Basic) (0.83) (2.85)

For the full year ended March 31, 2026, the company reported a net loss of ₹3,409.03 lakh on a total income of ₹2,534.05 lakh. The auditor emphasized the write-off of Capital Work-in-Progress amounting to ₹46.27 lakh during the year as an exceptional item. The company faces significant operational challenges, including labour unrest and obstruction by an unrecognized union preventing access to the factory for damage assessment. The management stated it is exploring alternative options such as contract manufacturing or leasing the facility to restore operations.

Historical Stock Returns for Lasa Supergenerics

1 Day5 Days1 Month6 Months1 Year5 Years
-0.84%+1.71%+2.72%-12.80%-47.96%-89.34%

What is the estimated timeline for resuming production at the Ratnagiri factory given the ongoing labor unrest?

How will the company fund operations and fixed costs during the extended halt in production?

What specific steps will management take to address the auditor's concerns regarding the impairment assessment of intangible assets?

More News on Lasa Supergenerics

1 Year Returns:-47.96%